Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990364 | 0.91 | FAP (0.35) | FAPCCNE1CDK2KDM4EALDH1A1 | |
| SCHEMBL4270182 | 0.88 | FAP (0.37) | FAPHPRT1POLBCYP3A4CCNE1 | |
| SCHEMBL4263493 | 0.87 | KDM4E (0.44) | FAPKDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL4267905 | 0.87 | FAP (0.36) | FAPHPRT1POLBCYP3A4CCNE1 | |
| SCHEMBL2905785 | 0.85 | FAP (0.35) | FAPPOLB | |
| SCHEMBL2990362 | 0.84 | FAP (0.34) | FAPCCNE1CDK2HSP90AA1HSP90AB1 | |
| SCHEMBL4266002 | 0.84 | HK1 (0.34) | FAPHSP90AA1HSP90AB1 | |
| SCHEMBL4271091 | 0.82 | CYP1A2 (0.35) | FAPCYP3A4HPGD | |
| SCHEMBL2942828 | 0.80 | FAP (0.35) | FAPCCNE1CDK2KDM4EALDH1A1 | |
| SCHEMBL3288110 | 0.79 | POLB (0.38) | HPRT1POLBCYP3A4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | claimed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | claimed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | FAP 2016/4885HPRT1 34/4885POLB 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.